1例舒尼替尼致肾脏血栓性微血管病变及肾病综合征报道  

A case report of renal-limited thrombotic microangiopathy and nephrotic syndrome induced by sunitiniband

作　　者：吴小芳 徐缓[2] 李孜[1] WU Xiao-fang;XU Huan;LI zi(Depatment of Nephrology,West China Hospital,Sichuan University,Chengdu 610041,China;Department of Pathology,West China Hospital,Sichuan University,Chengdu 610041,China)

机构地区：[1]四川大学华西医院肾脏内科,成都610041 [2]四川大学华西医院病理科,成都610041

出　　处：《临床药物治疗杂志》2019年第10期85-89,共5页Clinical Medication Journal

摘　　要：舒尼替尼是一种口服多靶点酪氨酸激酶抑制剂,具有抗肿瘤、抗血管增生的作用。该药对肾脏的损伤多表现为非肾病范围蛋白尿,导致肾病综合征相对少见,国内尚无舒尼替尼引起肾脏血栓性微血管病变报道。本文报道1例胃间质瘤术后接受舒尼替尼治疗患者,出现肾病综合征伴肾功能减退,肾活检证实为血栓性微血管病变,同时结合相关文献,对舒尼替尼所致肾脏损伤的临床表现、发病机制及治疗方法进行讨论,以提高对此类药物肾脏损伤的认识与重视。Sunitinib is an oral,multitargeted receptor tyrosine kinase inhibitor,which has been used for the treatment of some advanced carcinoma Proteinuria has been reported to be associated with the use of sunitinib.However,nephrotic syndrome seldom happened and there had no report of renal-limited thrombotic microangiopathy due to the use of sunitinib in China.We report a patient who developed nephrotic syndrome and biopsy-proven thrombotic microangiopathy after the treatment with sunitinib,and make a discussion about the clinical manifestations,pathogenesis and treatment of sunitinib induced renal injury.

关 键 词：舒尼替尼 蛋白尿 肾病综合征 血栓性微血管病变 

分 类 号：R979.19[医药卫生—药品]